Clinical trial results:
Follow-Up Study in Patients with Acromegaly Previously Participating in Chiasma Study CH-ACM-01

Summary

EudraCT number	2015-001292-51
Trial protocol	DE HU SI PL IT
Global end of trial date	12 January 2016

Results information

Result version number	v1 (current)
This version publication date	23 December 2018
First version publication date	23 December 2018

Trial information

Trial identification

Sponsor protocol code	CH-ACM-01-FU

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Chiasma, Inc.
Sponsor organisation address	460 Totten Pond Road, Suite 530, Waltham, Massachusetts, United States, 02451
Public contact	William H. Ludlam, Sr. VP Clinical Development and Medical Affairs, Chiasma, Inc., William H. Ludlam, Sr. VP Clinical Development and Medical Affairs, Chiasma, Inc., 1 6179285294, william.ludlam@chiasmapharma.com
Scientific contact	Asi Haviv, VP Clinical Development, Chiasma, Inc., Asi Haviv, VP Clinical Development, Chiasma, Inc., 972 89393888, Asi@chiasmapharma.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	12 January 2016
Is this the analysis of the primary completion data?	Yes
Primary completion date	12 January 2016
Global end of trial reached?	Yes
Global end of trial date	12 January 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This was a non-interventional, observational study. The objective was to assess reinitiation of standard of care medical treatment for acromegaly, following the completion of study CH-ACM-01, where patient were treated with Octreotide Capsules (previously called oral octreolin).
Group 1 were patients who did not reinitiate standard of care acromegaly treatment within the 2 weeks follow up period, following completion of CH-ACM-01. For this group the objective was to investigate if standard of care treatment for acromegaly was reinitiated following the completion of the study.
Group 2 were patients who reinitiated standard of care acromegaly treatment within the 2 weeks follow up period and were responders to octreotide capsules at the end of study CH-ACM-01. For this group the objective was to assess the rationale for reinitiation of standard of care medical treatment for acromegaly.

Protection of trial subjects:

Not applicable

Background therapy:

In both groups, patients were treated/could reinitiate treatment with standard of care treatment for acromegaly per best clinical practice.

Evidence for comparator:

Not applicable

Actual start date of recruitment	29 May 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Poland: 8
Country: Number of subjects enrolled	Romania: 9
Country: Number of subjects enrolled	Slovenia: 2
Country: Number of subjects enrolled	Germany: 10
Country: Number of subjects enrolled	Hungary: 11
Country: Number of subjects enrolled	Italy: 4
Country: Number of subjects enrolled	Lithuania: 3
Country: Number of subjects enrolled	Netherlands: 10
Country: Number of subjects enrolled	Serbia: 7
Country: Number of subjects enrolled	Slovakia: 4
Country: Number of subjects enrolled	United Kingdom: 10
Country: Number of subjects enrolled	Israel: 9

Worldwide total number of subjects	87
EEA total number of subjects	71

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	67
From 65 to 84 years	20
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

The study was a follow-up study of trial CH-ACM-01 and was performed in centers that previously participated in that study. Patients who completed study CH-ACM-01 were invited to participate. Information was collected retrospectively from eligible patients and documented. No study drug was administered.

Pre-assignment

Screening details:

Acromegaly patients who previously participated in and completed study CH-ACM-01.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Blinding implementation details:

Not applicable

Arms

Are arms mutually exclusive?	Yes
Arm title	Group 1 (no new acromegaly treatment)

Arm description:

Patients who had completed trial CH-ACM-01 and did not initiate new acromegaly therapy, or patients for whom data on new acromegaly therapy is missing.

Arm type	Standard of care
Investigational medicinal product name	Standard of care
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion, Tablet
Routes of administration	Oral use, Subcutaneous use, Intramuscular use

Dosage and administration details:

Patients received standard of care, including injectable somatostatin receptor ligands, dopamine agonists, growth Hormone Antagonist, or no treatment

Arm title	Group 2 (new acromegaly therapy)

Arm description:

Patients who responded to MYCAPSSA Treatment (oral octreotide) in study CH-ACM-01 and who initiated new acromegaly Treatment after completion of Trial CH-ACM-01

Arm type	Standard of care
Investigational medicinal product name	Standard of care
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection/infusion, Tablet
Routes of administration	Intravenous use, Oral use, Subcutaneous use

Dosage and administration details:

Patients received standard of care, including injectable somatostatin receptor ligands, dopamine agonists, growth Hormone Antagonist, or no treatment

Investigational medicinal product name	Standard of care
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet, Solution for injection/infusion
Routes of administration	Oral use, Subcutaneous use, Intramuscular use

Dosage and administration details:

Patients received standard of care, including injectable somatostatin receptor ligands, dopamine agonists, growth Hormone Antagonist, or no treatment

Number of subjects in period 1	Group 1 (no new acromegaly treatment)	Group 2 (new acromegaly therapy)
Started	26	61
Completed	26	61

Baseline characteristics

Reporting groups	
Reporting group title	Group 1 (no new acromegaly treatment)
Reporting group description:	
Patients who had completed trial CH-ACM-01 and did not initiate new acromegaly therapy, or patients for whom data on new acromegaly therapy is missing.	
Reporting group title	Group 2 (new acromegaly therapy)
Reporting group description:	
Patients who responded to MYCAPSSA Treatment (oral octreotide) in study CH-ACM-01 and who initiated new acromegaly Treatment after completion of Trial CH-ACM-01	

Reporting group values	Group 1 (no new acromegaly treatment)	Group 2 (new acromegaly therapy)	Total
Number of subjects	26	61	87
Age categorical			
Units: Subjects			
Adults (18-64 years)	21	46	67
From 65-84 years	5	15	20
Age continuous			
Units: years			
arithmetic mean	54.4	54.4	
standard deviation	± 10.2	± 12.9	-
Gender categorical			
Units: Subjects			
Female	17	29	46
Male	9	32	41
Insuline like growth factor I			
The Plasma Level of Insuline like growth factor I at the end of the main study period CH-ACM-01 was the baseline value for patients in this follow-up study, CH-ACM-01 FU			
Units: Multiples of the upper limit of normal			
arithmetic mean	1.03	0.92	
standard deviation	± 0.70	± 0.51	-

End points

End points reporting groups

Reporting group title	Group 1 (no new acromegaly treatment)
Reporting group description:	
Patients who had completed trial CH-ACM-01 and did not initiate new acromegaly therapy, or patients for whom data on new acromegaly therapy is missing.	
Reporting group title	Group 2 (new acromegaly therapy)
Reporting group description:	
Patients who responded to MYCAPSSA Treatment (oral octreotide) in study CH-ACM-01 and who initiated new acromegaly Treatment after completion of Trial CH-ACM-01	

Primary: Proportion of patients initiating acromegaly treatment

End point title	Proportion of patients initiating acromegaly treatment[1][2]
End point description:	
Proportion of patients initiating acromegaly treatment. This endpoint was analysed for Group 1 only.	
End point type	Primary
End point timeframe:	
This was a follow-up, retrospective, non-interventional study of patients with acromegaly who previously participated in study CH-ACM-01 where they were treated with MYCAPSSA. Follow up occured between 1.5-2.5 years after completion of study CH-ACM-01.	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This study was descriptive in nature, with no formal primary hypothesis testing.

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In line with the objectives of the trial, this primary endpoint was only analysed for Group 1 of the Trial Population.

End point values	Group 1 (no new acromegaly treatment)			
Subject group type	Reporting group			
Number of subjects analysed	26			
Units: Patients	22			

Statistical analyses

No statistical analyses for this end point

Primary: Reasons for reinitiating acromegaly treatment

End point title	Reasons for reinitiating acromegaly treatment[3][4]
End point description:	
Reasons for patients to reinitiate acromegaly treatment. This endpoint was analysed for Group 2 only.	
End point type	Primary
End point timeframe:	
This was a follow-up, retrospective, non-interventional study of patients with acromegaly who previously	

participated in study CH-ACM-01 where they were treated with MYCAPSSA. Follow up occured between 1.5-2.5 years after completion of study CH-ACM-01.

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
Justification: This study was descriptive in nature, with no formal primary hypothesis testing.

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: In line with the objectives of the trial, this primary endpoint was only analysed for Group 2 of the Trial Population.

End point values	Group 2 (new acromegaly therapy)			
Subject group type	Reporting group			
Number of subjects analysed	61			
Units: Patients				
Known disease history requiring chronic treatment	31			
Achieve/maintain biochemical disease control	19			
Active clinical symptoms	4			
Clinical routine/no specific reasons	6			
Other reason	1			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information[1]

Timeframe for reporting adverse events:

Four-week follow-up period (The study duration for each eligible patient did not exceed 4 weeks from the time of signing ICF to complete capture of the requested information).

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	14

Reporting groups

Reporting group title	Group 1 (no new acromegaly treatment)

Reporting group description:

Patients who had completed trial CH-ACM-01 and did not initiate new acromegaly therapy, or patients for whom data on new acromegaly therapy is missing.

Reporting group title	Group 2 (new acromegaly therapy)

Reporting group description:

Patients who responded to MYCAPSSA Treatment (oral octreotide) in study CH-ACM-01 and who initiated new acromegaly Treatment after completion of Trial CH-ACM-01

Serious adverse events	Group 1 (no new acromegaly treatment)	Group 2 (new acromegaly therapy)	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 26 (0.00%)	0 / 61 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events: 1 %

Non-serious adverse events	Group 1 (no new acromegaly treatment)	Group 2 (new acromegaly therapy)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	0 / 26 (0.00%)	0 / 61 (0.00%)	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: This was a non-interventional study. Data on medical treatment for acromegaly were collected from patient files. Adverse events were not collected.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

Not applicable

Notes: